Resmed Other Current Liab vs Short Long Term Debt Total Analysis
RMD Stock | 38.40 0.19 0.49% |
Resmed financial indicator trend analysis is much more than just breaking down Resmed Inc DRC prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Resmed Inc DRC is a good investment. Please check the relationship between Resmed Other Current Liab and its Short Long Term Debt Total accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Resmed Inc DRC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Other Current Liab vs Short Long Term Debt Total
Other Current Liab vs Short Long Term Debt Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Resmed Inc DRC Other Current Liab account and Short Long Term Debt Total. At this time, the significance of the direction appears to have very week relationship.
The correlation between Resmed's Other Current Liab and Short Long Term Debt Total is 0.27. Overlapping area represents the amount of variation of Other Current Liab that can explain the historical movement of Short Long Term Debt Total in the same time period over historical financial statements of Resmed Inc DRC, assuming nothing else is changed. The correlation between historical values of Resmed's Other Current Liab and Short Long Term Debt Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Liab of Resmed Inc DRC are associated (or correlated) with its Short Long Term Debt Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Long Term Debt Total has no effect on the direction of Other Current Liab i.e., Resmed's Other Current Liab and Short Long Term Debt Total go up and down completely randomly.
Correlation Coefficient | 0.27 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Other Current Liab
Short Long Term Debt Total
Most indicators from Resmed's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Resmed Inc DRC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Resmed Inc DRC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. Selling General Administrative is likely to drop to about 709.4 M in 2024. Tax Provision is likely to drop to about 182 M in 2024
2022 | 2023 | 2024 (projected) | Total Revenue | 4.2B | 4.7B | 4.9B | Depreciation And Amortization | 197.6M | 216.2M | 227.0M |
Resmed fundamental ratios Correlations
Click cells to compare fundamentals
Resmed Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Resmed fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 4.6B | 4.7B | 5.1B | 6.8B | 6.9B | 7.2B | |
Short Long Term Debt Total | 1.3B | 793.7M | 917.6M | 1.6B | 873.9M | 442.7M | |
Other Current Liab | (54.2M) | 304.1M | 389.6M | 365.7M | 350.7M | 368.2M | |
Total Current Liabilities | 602.8M | 911.8M | 689.3M | 758.5M | 910.7M | 956.2M | |
Total Stockholder Equity | 2.5B | 2.9B | 3.4B | 4.1B | 4.9B | 5.1B | |
Property Plant And Equipment Net | 535.7M | 592.1M | 630.5M | 665.8M | 699.1M | 734.1M | |
Net Debt | 836.1M | 498.4M | 643.8M | 1.4B | 635.6M | 667.4M | |
Retained Earnings | 2.8B | 3.1B | 3.6B | 4.3B | 5.0B | 5.2B | |
Accounts Payable | 135.8M | 138.0M | 159.2M | 150.8M | 237.7M | 249.6M | |
Cash | 463.2M | 295.3M | 273.7M | 227.9M | 238.4M | 333.5M | |
Non Current Assets Total | 3.1B | 3.2B | 3.2B | 4.4B | 4.5B | 4.7B | |
Non Currrent Assets Other | 189.7M | 240.8M | 251.5M | 395.4M | 487.6M | 511.9M | |
Cash And Short Term Investments | 463.2M | 295.3M | 273.7M | 227.9M | 238.4M | 338.0M | |
Common Stock Shares Outstanding | 1.5B | 1.5B | 1.5B | 1.5B | 147.6M | 140.2M | |
Liabilities And Stockholders Equity | 4.6B | 4.7B | 5.1B | 6.8B | 6.9B | 7.2B | |
Non Current Liabilities Total | 1.5B | 930.7M | 1.0B | 1.9B | 1.1B | 1.2B | |
Inventory | 416.9M | 457.0M | 743.9M | 998.0M | 822.3M | 863.4M | |
Other Current Assets | 168.7M | 296.5M | 337.9M | 437.0M | 459.8M | 482.8M | |
Other Stockholder Equity | (389.7M) | (415.9M) | 59.2M | 148.8M | 123.3M | 129.5M | |
Total Liab | 2.1B | 1.8B | 1.7B | 2.6B | 2.0B | 2.1B | |
Total Current Assets | 1.5B | 1.6B | 1.9B | 2.4B | 2.4B | 2.5B | |
Short Term Debt | 33.3M | 35.6M | 31.8M | 31.8M | 35.2M | 66.5M | |
Intangible Assets | 448.2M | 392.6M | 345.9M | 552.3M | 485.9M | 510.2M | |
Accumulated Other Comprehensive Income | (284.0M) | (193.5M) | (312.7M) | (272.5M) | (251.5M) | (239.0M) | |
Common Stock | 580K | 583K | 586K | 588K | 676.2K | 443.7K | |
Current Deferred Revenue | 98.6M | 109.6M | 108.7M | 138.1M | 152.6M | 160.2M | |
Good Will | 1.9B | 1.9B | 1.9B | 2.8B | 2.8B | 3.0B | |
Other Liab | 221.6M | 172.6M | 160.0M | 315.2M | 362.5M | 380.6M | |
Net Tangible Assets | 158.5M | 565.2M | 1.1B | 807.3M | 726.5M | 539.8M | |
Other Assets | 145.6M | 200.7M | 202.3M | 261.3M | 300.5M | 161.7M | |
Long Term Debt | 1.2B | 643.4M | 765.3M | 1.4B | 697.3M | 878.4M | |
Short Long Term Debt | 12.0M | 12M | 9.9M | 9.9M | 9.9M | 9.4M | |
Property Plant Equipment | 535.7M | 592.1M | 630.5M | 665.8M | 765.7M | 527.8M | |
Long Term Debt Total | 1.3B | 1.2B | 643.4M | 765.3M | 688.8M | 691.8M | |
Capital Surpluse | 1.5B | 1.6B | 1.6B | 1.7B | 1.9B | 1.7B |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Resmed Stock Analysis
When running Resmed's price analysis, check to measure Resmed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Resmed is operating at the current time. Most of Resmed's value examination focuses on studying past and present price action to predict the probability of Resmed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Resmed's price. Additionally, you may evaluate how the addition of Resmed to your portfolios can decrease your overall portfolio volatility.